AB001 (²¹²Pb-NG001)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1/2Active - First patient dosed in ARTISAN trial (Jan 2026)
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 1/2
Status
Active - First patient dosed in ARTISAN trial (Jan 2026)
Company
About ARTBIO
ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| PNT2002 | Lantheus Holdings | Phase 3 |
| JANX007 | Janux Therapeutics | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| INKmune | INmune Bio | Phase 1/2 |